These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 35095921)

  • 1. Use of a
    Lang GA; Norman K; Amadou Amani S; Shadid TM; Ballard JD; Lang ML
    Front Immunol; 2021; 12():818734. PubMed ID: 35095921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. α-Galactosylceramide-Reactive NKT Cells Increase IgG1 Class Switch against a Clostridioides difficile Polysaccharide Antigen and Enhance Immunity against a Live Pathogen Challenge.
    Lang GA; Shrestha B; Amadou Amani S; Shadid TM; Ballard JD; Lang ML
    Infect Immun; 2021 Oct; 89(11):e0043821. PubMed ID: 34424751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety in rabbits of a Clostridioides difficile vaccine combining novel toxoids and a novel adjuvant.
    Aminzadeh A; Hilgers L; Paul Platenburg P; Riou M; Perrot N; Rossignol C; Cauty A; Barc C; Jørgensen R
    Vaccine; 2024 Mar; 42(7):1582-1592. PubMed ID: 38336558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coordination between T helper cells, iNKT cells, and their follicular helper subsets in the humoral immune response against Clostridium difficile toxin B.
    Rampuria P; Lang GA; Devera TS; Gilmore C; Ballard JD; Lang ML
    J Leukoc Biol; 2017 Feb; 101(2):567-576. PubMed ID: 27566831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type II NKT cells facilitate Alum-sensing and humoral immunity.
    Shah HB; Devera TS; Rampuria P; Lang GA; Lang ML
    J Leukoc Biol; 2012 Oct; 92(4):883-93. PubMed ID: 22798686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving the Th1 cellular efficacy of the lead Yersinia pestis rF1-V subunit vaccine using SA-4-1BBL as a novel adjuvant.
    Dinc G; Pennington JM; Yolcu ES; Lawrenz MB; Shirwan H
    Vaccine; 2014 Sep; 32(39):5035-40. PubMed ID: 25045812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant.
    Li X; Fujio M; Imamura M; Wu D; Vasan S; Wong CH; Ho DD; Tsuji M
    Proc Natl Acad Sci U S A; 2010 Jul; 107(29):13010-5. PubMed ID: 20616071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of anthrax toxin-specific antibody titers by natural killer T cell-derived IL-4 and IFNγ.
    Devera TS; Joshi SK; Aye LM; Lang GA; Ballard JD; Lang ML
    PLoS One; 2011; 6(8):e23817. PubMed ID: 21858226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
    Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
    Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycolipid-activated NKT cells support the induction of persistent plasma cell responses and antibody titers.
    Devera TS; Shah HB; Lang GA; Lang ML
    Eur J Immunol; 2008 Apr; 38(4):1001-11. PubMed ID: 18350547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunization-Expanded NKT Follicular Helper Cells Drive IgG1 Isotype Switch against an Exogenous T-Independent Polysaccharide but Do Not Promote Recall Responses.
    Lang GA; Amadou Amani S; Quinn JL; Axtell RC; Lang ML
    Immunohorizons; 2019 Mar; 3(3):88-93. PubMed ID: 31342012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BAFF- and APRIL-dependent maintenance of antibody titers after immunization with T-dependent antigen and CD1d-binding ligand.
    Shah HB; Joshi SK; Rampuria P; Devera TS; Lang GA; Stohl W; Lang ML
    J Immunol; 2013 Aug; 191(3):1154-63. PubMed ID: 23797666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing NKT cell ligands as vaccine adjuvants.
    Carreño LJ; Kharkwal SS; Porcelli SA
    Immunotherapy; 2014; 6(3):309-20. PubMed ID: 24762075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical development of a novel CD1d-binding NKT cell ligand as a vaccine adjuvant.
    Padte NN; Li X; Tsuji M; Vasan S
    Clin Immunol; 2011 Aug; 140(2):142-51. PubMed ID: 21185784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic antibody responses induced by a two-component Clostridium difficile toxoid vaccine protect against C. difficile-associated disease in hamsters.
    Anosova NG; Brown AM; Li L; Liu N; Cole LE; Zhang J; Mehta H; Kleanthous H
    J Med Microbiol; 2013 Sep; 62(Pt 9):1394-1404. PubMed ID: 23518659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular features of lipoprotein CD0873: A potential vaccine against the human pathogen
    Bradshaw WJ; Bruxelle JF; Kovacs-Simon A; Harmer NJ; Janoir C; Péchiné S; Acharya KR; Michell SL
    J Biol Chem; 2019 Oct; 294(43):15850-15861. PubMed ID: 31420448
    [No Abstract]   [Full Text] [Related]  

  • 17. Improving Mycobacterium bovis bacillus Calmette-Guèrin as a vaccine delivery vector for viral antigens by incorporation of glycolipid activators of NKT cells.
    Venkataswamy MM; Ng TW; Kharkwal SS; Carreño LJ; Johnson AJ; Kunnath-Velayudhan S; Liu Z; Bittman R; Jervis PJ; Cox LR; Besra GS; Wen X; Yuan W; Tsuji M; Li X; Ho DD; Chan J; Lee S; Frothingham R; Haynes BF; Panas MW; Gillard GO; Sixsmith JD; Korioth-Schmitz B; Schmitz JE; Larsen MH; Jacobs WR; Porcelli SA
    PLoS One; 2014; 9(9):e108383. PubMed ID: 25255287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naloxone and alum synergistically augment adjuvant activities of each other in a mouse vaccine model of Salmonella typhimurium infection.
    Jazani NH; Parsania S; Sohrabpour M; Mazloomi E; Karimzad M; Shahabi S
    Immunobiology; 2011 Jun; 216(6):744-51. PubMed ID: 21093956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD1d-dependent B-cell help by NK-like T cells leads to enhanced and sustained production of Bacillus anthracis lethal toxin-neutralizing antibodies.
    Devera TS; Aye LM; Lang GA; Joshi SK; Ballard JD; Lang ML
    Infect Immun; 2010 Apr; 78(4):1610-7. PubMed ID: 20123711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A potent adjuvant effect of a CD1d-binding NKT cell ligand in human immune system mice.
    Li X; Huang J; Kaneko I; Zhang M; Iwanaga S; Yuda M; Tsuji M
    Expert Rev Vaccines; 2017 Jan; 16(1):73-80. PubMed ID: 27801602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.